SCHEMBL6444660

SCHEMBL6444660

C[S+]([O-])c1nc(N)nc(Cl)c1C#N

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.43
GAA P10253 3/20 0.35
KDM4E B2RXH2 2/20 0.35
MEN1 O00255 2/20 0.35
MAPT P10636 2/20 0.35
KMT2A Q03164 2/20 0.35
L3MBTL1 Q9Y468 2/20 0.35
CACNA1B Q00975 1/20 0.35
APBA1 Q02410 1/20 0.35
APOBEC3G Q9HC16 1/20 0.35
CHUK O15111 1/20 0.34
ADORA1 P30542 8/20 0.33
ADORA2A P29274 6/20 0.33
ADORA2B P29275 2/20 0.33
HTT P42858 4/20 0.32
MAPK1 P28482 2/20 0.32
LMNA P02545 2/20 0.32
PKM P14618 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32
GLA P06280 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL963677 0.77 ALDH1A1 (0.45) ALDH1A1GAAKDM4EMEN1MAPT
SCHEMBL17458364 0.77 ALDH1A1 (0.54) ALDH1A1GAAKDM4EMEN1MAPT
SCHEMBL11040256 0.76 ADORA2A (0.31) ADORA1ADORA2A
SCHEMBL6441373 0.72 ADORA1 (0.67) ADORA1ADORA2AADORA2B
SCHEMBL31575894 0.72 ALDH1A1 (0.55) ALDH1A1GAAKDM4EMEN1MAPT
SCHEMBL11900926 0.72 ALDH1A1 (0.55) ALDH1A1GAAKDM4EMEN1MAPT
SCHEMBL13729450 0.71 ALDH1A1 (0.59) ALDH1A1GAAKDM4EMEN1MAPT
SCHEMBL6444984 0.70 ADORA1 (0.62) CHUKADORA1ADORA2AADORA2B
SCHEMBL6443065 0.69 CYP1A2 (0.49) ALDH1A1MEN1MAPTKMT2AL3MBTL1
SCHEMBL6445313 0.68 ADORA2A (0.53) ADORA1ADORA2AADORA2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1261327-B1 ADENOSINE RECEPTOR MODULATORS HOFFMANN LA ROCHE (CH) 2005-04-27 EP disclosed
CN-1438890-A Adenosine receptor modulators HOFFMANNLA ROCHE AG F (CH) 2003-08-27 CN disclosed
US-6586441-B2 2-Amino-6-benzylsulfanyl-4-thiophen-2-yl-pyridine-3,5-dicarbo -nitrile as an examplary preferred compound; Alzheimer's and Parkinson's diseases; neuroprotectors; schizophrenia, analgesics; anxiolytic agents; respiratory disorders HOFFMAN-LA ROCHE INC. 2003-07-01 US disclosed
EP-1261327-A2 ADENOSINE RECEPTOR MODULATORS F.HOFFMANN-LA ROCHE AG (CH) 2002-12-04 EP disclosed
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease F. HOFFMANN-LA ROCHE AG (CH) 2001-10-04 US disclosed
WO-2001062233-A2 ADENOSINE RECEPTOR MODULATORS F. HOFFMANN LA ROCHE AG (CH) 2001-08-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease ADORA2A, ADORA2B, ADORA1 ALDH1A1 534/4885GAA 373/4885KDM4E 3250/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.